Brief: Algernon Pharmaceuticals To File End-Of-Phase 2 Meeting Request With U.S. FDA For Possible Ifenprodil Phase 3 Covid-19 Trial
08/04/2021 12:18
April 8 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS TO FILE END-OF-PHASE 2 MEETING
REQUEST
WITH U.S. FDA FOR POSSIBLE IFENPRODIL PHASE 3 COVID-19 TRIAL
Source text for Eikon: ID:nGNXbPR67y
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement